{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013095","form_type":"8-K","ticker":"GCTK","cik":"0001506983","company_name":"Glucotrack, Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.264650+00:00","generated_at":"2026-05-15T08:36:53.097488+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Glucotrack to file IDE with FDA for implantable CBGM in Q2 2026, citing positive trial results","bullets":["Brazil first-in-human study (Dec 2024-Jan 2025) showed MARD 7.7%, 99% data capture, and zero serious adverse events.","Australia feasibility study started July 2025; findings are incorporated for planned US trial.","Three US patents issued Oct/Nov 2025 covering sensor chemistry, intravascular lead, and low-power electronics.","Expects to file IDE with FDA in Q2 2026 and initiate US clinical study in H2 2026, pending approval.","Reinforced commercial foundation: market research, reimbursement pathway, dual-source manufacturing, seasoned leadership."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013095","json":"https://secwatch.observer/filing/0001493152-26-013095.json","markdown":"https://secwatch.observer/filing/0001493152-26-013095.md","text":"https://secwatch.observer/filing/0001493152-26-013095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226013095/0001493152-26-013095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226013095/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:36:53.097488+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}